WallStSmart

Omnicell Inc (OMCL)vsR1 RCM Inc (RCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

R1 RCM Inc generates 108% more annual revenue ($2.46B vs $1.18B). OMCL leads profitability with a 0.2% profit margin vs -2.5%. RCM appears more attractively valued with a PEG of 2.06. RCM earns a higher WallStSmart Score of 39/100 (F).

OMCL

Hold

39

out of 100

Grade: F

Growth: 2.7Profit: 4.0Value: 2.0Quality: 6.3
Piotroski: 4/9

RCM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

OMCLSignificantly Overvalued (-13907.4%)

Margin of Safety

-13907.4%

Fair Value

$0.27

Current Price

$34.94

$34.67 premium

UndervaluedFair: $0.27Overvalued

Intrinsic value data unavailable for RCM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

OMCL2 strengths · Avg: 9.5/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

RCM1 strengths · Avg: 8.0/10
Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

OMCL4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
2.3%4/10

2.3% revenue growth

Market CapQuality
$1.57B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.2%3/10

ROE of 0.2% — below average capital efficiency

Profit MarginProfitability
0.2%3/10

0.2% margin — thin

RCM4 concerns · Avg: 2.8/10
PEG RatioValuation
2.064/10

Expensive relative to growth rate

Operating MarginProfitability
3.8%3/10

Operating margin of 3.8%

Return on EquityProfitability
-2.2%2/10

ROE of -2.2% — below average capital efficiency

EPS GrowthGrowth
-99.3%2/10

Earnings declined 99.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : OMCL

The strongest argument for OMCL centers on Price/Book, Debt/Equity.

Bull Case : RCM

The strongest argument for RCM centers on Price/Book. Revenue growth of 14.7% demonstrates continued momentum.

Bear Case : OMCL

The primary concerns for OMCL are Revenue Growth, Market Cap, Return on Equity. A P/E of 861.5x leaves little room for execution misses. Thin 0.2% margins leave little buffer for downturns.

Bear Case : RCM

The primary concerns for RCM are PEG Ratio, Operating Margin, Return on Equity.

Key Dynamics to Monitor

OMCL profiles as a value stock while RCM is a turnaround play — different risk/reward profiles.

RCM carries more volatility with a beta of 0.84 — expect wider price swings.

RCM is growing revenue faster at 14.7% — sustainability is the question.

RCM generates stronger free cash flow (60M), providing more financial flexibility.

Bottom Line

OMCL scores higher overall (39/100 vs 39/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Omnicell Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Omnicell, Inc., provides medication management automation solutions and adherence tools for health care systems and pharmacies in the United States and internationally. The company is headquartered in Mountain View, California.

R1 RCM Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

R1 RCM Inc (RCM) is a leading provider of technology-enabled revenue cycle management services, specializing in optimizing the financial performance of healthcare organizations. By leveraging advanced analytics and industry expertise, R1 RCM delivers comprehensive solutions that streamline patient billing processes and enhance operational efficiencies across a diverse portfolio of clients, including hospitals and outpatient facilities. The company's innovative approach not only improves revenue capture but also elevates the patient experience, positioning R1 RCM as a key player in the evolving healthcare landscape. With a robust growth strategy focused on expanding its service offerings and market reach, R1 RCM is poised to capitalize on the increasing demand for effective revenue cycle solutions in the healthcare sector.

Want to dig deeper into these stocks?